Horizon secures FDA priority review for teprotumumab for treatment of active thyroid eye...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 10, 2019 at 9:52 AM.

  1. #1 cafead, Sep 10, 2019 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation.

    article source
     
    Quote

Reply to Thread